Literature DB >> 31068319

Preventing medication-related osteonecrosis of the jaw.

Lara Zebic1, Vinod Patel2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31068319     DOI: 10.1136/bmj.l1733

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  3 in total

1.  Photodynamic Therapy as an adjunct in the Treatment of Medication-Related Osteonecrosis of the Jaw: A Case Report.

Authors:  Marcelo Vieira da Costa Almeida; Antonio C Moura; Lúcia Santos; Luciana Gominho; Ully Dias Nascimento Távora Cavalcanti; Kaline Romeiro
Journal:  J Lasers Med Sci       Date:  2021-03-08

2.  Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation.

Authors:  Wen Guo; Haijun Li; Yan Lou; Yue Zhang; Jia Wang; Ming Qian; Haifeng Wei; Jianru Xiao; Youjia Xu
Journal:  J Orthop Translat       Date:  2021-04-10       Impact factor: 5.191

3.  Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-κB pathway.

Authors:  Yajun Li; Qi Zhuang; Lihong Tao; Kai Zheng; Shuangshuang Chen; Yunshang Yang; Chengcheng Feng; Zhifang Wang; Haiwei Shi; Jiandong Shi; Yiling Fang; Long Xiao; Dechun Geng; Zhirong Wang
Journal:  Cell Prolif       Date:  2022-06-16       Impact factor: 8.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.